Evoke Pharma Inc Cash Flow Conversion Efficiency
Evoke Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Evoke Pharma Inc (EVOK) has a cash flow conversion efficiency ratio of -0.155x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-521.96K) by net assets ($3.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Evoke Pharma Inc (2011–2024)
Cash flow conversion efficiency of Evoke Pharma Inc from 2011 to 2024. This chart illustrates how Evoke Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Evoke Pharma Inc (EVOK) stock price for real-time trading data and today's change.
Evoke Pharma Inc Cash Flow Conversion Ratio Explained
Evoke Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Evoke Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evoke Pharma Inc ranked by their cash flow conversion efficiency. Also see EVOK market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Race Eco Chain Limited
NSE:RACE
|
0.039x |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
0.893x |
|
STS Group AG
XETRA:SF3
|
0.369x |
|
Elspec
TA:ELSPC
|
0.028x |
|
RENN Fund Inc
NYSE MKT:RCG
|
-0.001x |
|
Seko S.A.
WAR:SEK
|
-0.002x |
|
Pantheon International PLC
LSE:PIN
|
-0.007x |
|
Is Yatirim Ortakligi AS
IS:ISYAT
|
0.069x |
Annual Cash Flow Conversion Efficiency for Evoke Pharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Evoke Pharma Inc from 2011 to 2024. Review EVOK financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.04 Million | $-5.46 Million | -0.776x | -140.13% |
| 2023-12-31 | $-2.58 Million | $-4.98 Million | 1.933x | +219.67% |
| 2022-12-31 | $4.08 Million | $-6.60 Million | -1.615x | +53.53% |
| 2021-12-31 | $3.56 Million | $-12.35 Million | -3.475x | -268.47% |
| 2020-12-31 | $-3.21 Million | $-6.63 Million | 2.062x | +256.79% |
| 2019-12-31 | $4.38 Million | $-5.76 Million | -1.315x | +24.13% |
| 2018-12-31 | $4.03 Million | $-6.98 Million | -1.734x | +56.93% |
| 2017-12-31 | $2.17 Million | $-8.72 Million | -4.025x | -75.07% |
| 2016-12-31 | $3.79 Million | $-8.71 Million | -2.299x | +24.10% |
| 2015-12-31 | $3.46 Million | $-10.50 Million | -3.029x | -142.01% |
| 2014-12-31 | $9.19 Million | $-11.50 Million | -1.252x | -772.10% |
| 2013-12-31 | $21.18 Million | $-3.04 Million | -0.144x | -261.24% |
| 2012-12-31 | $-19.66 Million | $-1.75 Million | 0.089x | -45.68% |
| 2011-12-31 | $-17.65 Million | $-2.89 Million | 0.164x | -- |
About Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more